ClinicalTrials.gg
CompletedNCT06089135Short-CutUpdated Jan 23, 2026

Shockwave Lithoplasty Compared to Cutting Balloon Treatment in Calcified Coronary Disease - A Randomized Controlled Trial

An interventional study of Intravascular Lithotripsy and Cutting Balloon in Treatment in Calcified Coronary Disease, sponsored by Baim Institute for Clinical Research. Completed at 22 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Baim Institute for Clinical Research · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
413
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 274 studies in Coronary Disease with a site in United States — 12 open to participants now, 23 under way, 2 of them phase 3. Coronary Disease · United States.

Enrollment
66th of 184
413 · median 200
Started
2023
with 2 others
No phase
78 of 274
6 open now
Registered
263rd of 274
by date

Among the 274 studies in Coronary Disease with a site in United States, this one is the 66th largest by enrollment of the 184 interventional ones that give a count, is one of 3 that started in 2023, is one of 78 with no phase, and was the 263rd registered.

Coronary Disease

1,521 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

12 of the 274 studies in Coronary Disease with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 105 Coronary Disease studies recruiting now, 63 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 274 studies in Coronary Disease with a site in United States, or all of them as a file.
02

Study summary

The Short-Cut trial is a prospective, investigator-initiated, multicenter, randomized controlled trial that is designed to compare the efficacy of cutting balloon angioplasty vs. intravascular lithotripsy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.

Read the detailed description

The trial will be composed of two cohorts:

  • Patients treated with up-front rotational atherectomy
  • Patients in whom atherectomy is not planned

Randomization to either cutting balloon angioplasty or intravascular lithotripsy will occur as follows in the 2 cohorts:

  • After rotational atherectomy is safely completed In the rotational atherectomy arm
  • After safe and successful wire crossing in patients in whom atherectomy is not planned.

The trial is designed to demonstrate non-inferiority between cutting balloon angioplasty and intravascular lithotripsy in each cohort with regards to the primary endpoint of post-procedural stent area as measured by intravascular imaging at the site of maximal calcification.

03

Conditions studied

  • Treatment in Calcified Coronary Disease

Browse trials for

Keywords

  • Intravascular Lithoplasty
  • Cutting Balloon
  • Calcified Coronary Disease
  • Percutaneous Coronary Intervention
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Subject is > 21 years old 2. Subject with an indication for PCI for the treatment of a) stable coronary artery disease; b) unstable angina; or c) NSTEMI with evidence of down-trending biomarkers 3. Subject is willing and able to provide informed written consent Angiographic Inclusion Criteria

    1. The target lesion is a de novo native coronary lesion
    2. The target vessel is a native coronary artery with either:

      1. A stenosis > 70%; or,
      2. A stenosis > 50% and \<70% with evidence of ischemia via either positive stress test, FFR value \< 0.80 or RFR/iFR/DFR value \< 0.89
    3. The reference diameter of the target vessel is > 2.5mm and \< 4.0 mm at the lesion site
    4. The target lesion has evidence of significant calcium at the lesion site defined either as,

      1. The presence of radiopacities involving both sides of the arterial wall > 5mm and involving the target lesion on angiography
      2. the presence of > 270o arc of superficial calcium on intravascular imaging with a length > 5mm or the presence of 360o arc of superficial calcium

Exclusion criteria

Exclusion Criteria:

<!-- -->

  1. Patient is pregnant
  2. Patient is actively participating in another clinical trial
  3. Known \< 25%
  4. Ongoing Non-STEMI with rising biomarkers
  5. Cardiogenic shock or requirement for mechanical/pharmacologic hemodynamic support
  6. Planned use in the randomized lesion of a bare metal stent or non-stent treatment only
  7. Patient has a known allergy to contrast which cannot be adequately pre-treated
  8. Patient has a history of bleeding or coagulopathy and is unable to receive blood transfusion if needed
  9. Patient presents with STEMI
  10. Patient is unable to tolerate dual anti- therapy
  11. Patient has suffered a recent cerebrovascular event (stroke/) within last 30 days

    Angiographic Exclusion Criteria

<!-- -->

  1. Presence of large thrombus in the target vessel
  2. Inability to pass coronary guidewire across the lesion
  3. The target vessel has excessive tortuosity (Defined as presence of 2+ bends > 90o or 3+ bends > 75o) or other anatomic considerations that precludes intravascular imaging
  4. The target lesion is within a coronary artery bypass graft
  5. The target lesion involves a bifurcation lesion in which either a 2-stent strategy is planned or both branches are planned for calcium modification
  6. Coronary artery disease that requires surgical revascularization
  7. Angiographic or imaging evidence of dissection in the target vessel prior to randomization
  8. Investigator feels there is not equipoise regarding the treatment strategy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
413 participants (actual)

Study arms

  • Active comparator
    Intravascular Lithotripsy

    Device: Intravascular Lithotripsy

  • Active comparator
    Cutting Balloon

    Device: Cutting Balloon

Interventions

  • DeviceIntravascular Lithotripsy

    Intravascular lithotripsy will be performed with or without rotational atherectomy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.

  • DeviceCutting Balloon

    Cutting Balloon therapy will be performed with or without rotational atherectomy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.

06

What researchers measure

Primary outcomes

  1. Primary Endpoint

    Post-procedural stent area at the point of maximum calcification as measured by intravascular imaging

    Time frame: 30 days

Secondary outcomes

  1. Procedural Cost

    Time frame: Index procedure

  2. Procedural success

    Procedural success defined as stent delivery with a residual stenosis \< 20% in the absence of significant angiographic complication (e.g. severe dissection, perforation, abrupt closure or no-reflow) with final TIMI 3 flow in the target vessel and the absence of intra-procedural death

    Time frame: Index procedure

  3. Angiographic success

    Angiographic success defined as stent delivery with a residual stenosis \< 20% in the absence of significant angiographic complication (e.g. severe dissection, perforation, abrupt closure or no-reflow)

    Time frame: Index procedure

  4. Strategy success

    Strategy success defined as stent delivery with a residual stenosis \< 20% in the absence of significant angiographic complication (e.g., severe dissection, perforation, abrupt closure or no-reflow and not having to use an alternative calcium modification device (e.g. atherectomy device or specialty balloon other than routine non-compliant balloon)

    Time frame: Index procedure

  5. Peri-procedural Myocardial Infarction

    Peri-procedural Myocardial Infarction as defined by Academic Research Consortium-2

    Time frame: within 48 hours of index procedure

  6. In-hospital MACCE

    In-hospital MACCE defined as composite of all-cause death, unplanned urgent target vessel revascularization, unplanned cardiothoracic surgery, spontaneous myocardial infarction or stroke/TIA at hospital discharge.

    Time frame: hospitalization

  7. 30 Day MACCE

    30 Day MACCE defined as composite of all-cause death, unplanned target vessel revascularization, unplanned cardiothoracic surgery, spontaneous myocardial infarction or stroke/TIA at 30 days

    Time frame: 30 days

07

Study locations

22 sites
  • UAB Structural Heart and Valve Clinic
    Birmingham, Alabama 35233, United States
  • Banner Health
    Phoenix, Arizona 85012, United States
  • Honor Health
    Scottsdale, Arizona 13400, United States
  • UCSF Cardiology
    San Francisco, California 94117, United States
  • Yale School of Medicine
    New Haven, Connecticut 06510, United States
  • Saint Luke's
    Overland Park, Kansas 66207, United States
  • Maine Medical Center
    Portland, Maine 04102, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02115, United States
  • Beth Israel Deaconess Medcial Center
    Boston, Massachusetts 02215, United States
  • Henry Ford Health
    Detroit, Michigan 48202, United States
  • Capital Cardiology
    Albany, New York 12211, United States
  • Columbia Cardiology
    New York, New York 10032, United States
  • Columbia University Medical Center/ NewYork Presbyterian Hospital
    New York, New York 10032, United States
  • Christ Hospital
    Cincinnati, Ohio 45219, United States
  • UPMC
    Pittsburgh, Pennsylvania 15213, United States
  • Wellspan York Hospital
    York, Pennsylvania 17403, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Baylor Heart and Vascular Hospital
    Dallas, Texas 75226, United States
  • Houston Methodist
    Houston, Texas 77030, United States
  • Baylor Scott and White Health
    Plano, Texas 75024, United States
  • UVA Heart and Vascular Center
    Charlottesville, Virginia 22903, United States
  • University of Washington
    Seattle, Washington 98195, United States
08

References and documents

Publications

  • Shah M, Najam O, Bhindi R, De Silva K. Calcium Modification Techniques in Complex Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2021 May;14(5):e009870. doi: 10.1161/CIRCINTERVENTIONS.120.009870. Epub 2021 Jan 14. PubMed 33441017 ↗
  • Allali A, Toelg R, Abdel-Wahab M, Hemetsberger R, Kastrati A, Mankerious N, Traboulsi H, Elbasha K, Rheude T, Landt M, Geist V, Richardt G. Combined rotational atherectomy and cutting balloon angioplasty prior to drug-eluting stent implantation in severely calcified coronary lesions: The PREPARE-CALC-COMBO study. Catheter Cardiovasc Interv. 2022 Nov;100(6):979-989. doi: 10.1002/ccd.30423. Epub 2022 Oct 19. PubMed 36262074 ↗
  • Furuichi S, Tobaru T, Asano R, Watanabe Y, Takamisawa I, Seki A, Sumiyoshi T, Tomoike H. Rotational atherectomy followed by cutting-balloon plaque modification for drug-eluting stent implantation in calcified coronary lesions. J Invasive Cardiol. 2012 May;24(5):191-5. PubMed 22562910 ↗
  • Abdel-Wahab M, Toelg R, Byrne RA, Geist V, El-Mawardy M, Allali A, Rheude T, Robinson DR, Abdelghani M, Sulimov DS, Kastrati A, Richardt G. High-Speed Rotational Atherectomy Versus Modified Balloons Prior to Drug-Eluting Stent Implantation in Severely Calcified Coronary Lesions. Circ Cardiovasc Interv. 2018 Oct;11(10):e007415. doi: 10.1161/CIRCINTERVENTIONS.118.007415. PubMed 30354632 ↗
  • Mangieri A, Nerla R, Castriota F, Reimers B, Regazzoli D, Leone PP, Gasparini GL, Khokhar AA, Laricchia A, Giannini F, Casale F, Bezzeccheri A, Briguori C, Colombo A. Cutting balloon to optimize predilation for stent implantation: The COPS randomized trial. Catheter Cardiovasc Interv. 2023 Mar;101(4):798-805. doi: 10.1002/ccd.30603. Epub 2023 Feb 25. PubMed 36841945 ↗
  • Kereiakes DJ, Hill JM, Shlofmitz RA, Klein AJ, Riley RF, Price MJ, Herrmann HC, Bachinsky W, Waksman R, Stone GW; Disrupt CAD III Investigators. Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Arteries: 2-Year Results-Disrupt CAD III Study. JACC Cardiovasc Interv. 2023 Oct 9;16(19):2472-2474. doi: 10.1016/j.jcin.2023.07.010. Epub 2023 Sep 6. No abstract available. PubMed 37676225 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Aug 2025, 19 months.

Of 178 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 19 months is below that.

Counting every sponsor, half of 200 studies reached it within 25 months; a quarter within 14 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2023
First posted
Oct 18, 2023
StartActual
Dec 31, 2023
Primary completionActual
Aug 30, 2025
CompletionActual
Sep 30, 2025
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06089135
Lead sponsor
Baim Institute for Clinical Research
Collaborators
Robert W. Yeh, MD, Ajay Kirtane, MD, C. Michael Gibson, MS, MD, Kathleen Kearney, MD, Akiko Maehara, MD, Suzanne Baron, MD
Responsible party
Sponsor
First posted
Oct 18, 2023
Start date
Dec 31, 2023
Primary completion
Aug 30, 2025
Completion
Sep 30, 2025
Last update
Jan 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion